Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
Japan’s key reimbursement policy panel on November 14 approved the results of cost-effectiveness assessments (CEAs) for Pfizer’s anti-BCMA/CD3 bispecific antibody Elrexfio (elranatamab). The drug’s price is expected to be kept unchanged, with its CEA profile coming out favorable. Elrexfio joined…
To read the full story
Related Article
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
REGULATORY
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
- Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…